Literature DB >> 18802013

Inhibition of tumor necrosis factor alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase.

Marie-Ann Ewart1, Christine F Kohlhaas, Ian P Salt.   

Abstract

OBJECTIVE: Proatherosclerotic adhesion of leukocytes to the endothelium is attenuated by NO. As AMP-activated protein kinase (AMPK) regulates endothelial NO synthesis, we investigated the modulation of adhesion to cultured human aortic endothelial cells (HAECs) by AMPK. METHODS AND
RESULTS: HAECs incubated with the AMPK activator, AICAR, or expressing constitutively active AMPK demonstrated reduced TNFalpha-stimulated adhesion of promonocytic U-937 cells. Rapid inhibition of TNFalpha-stimulated U-937 cell adhesion by AICAR was NO-dependent, associated with unaltered cell surface adhesion molecule expression, and reduced MCP-1 secretion by HAECs. In contrast, inhibition of TNFalpha-stimulated U-937 cell adhesion by prolonged AMPK activation was NO-independent and associated with reduced cell surface adhesion molecule expression.
CONCLUSIONS: AMPK activation in HAECs inhibits TNFalpha-stimulated leukocyte adhesion by a rapid NO-dependent mechanism associated with reduced MCP-1 secretion and a late NO-independent mechanism whereby adhesion molecule expression, in particular E-selectin, is suppressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802013     DOI: 10.1161/ATVBAHA.108.175919

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  26 in total

1.  Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival.

Authors:  Xiao-ming Liu; Kelly J Peyton; Ahmad R Shebib; Hong Wang; Ronald J Korthuis; William Durante
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-29       Impact factor: 4.733

2.  Isoform-selective 5'-AMP-activated protein kinase-dependent preconditioning mechanisms to prevent postischemic leukocyte-endothelial cell adhesive interactions.

Authors:  F Spencer Gaskin; Kazuhiro Kamada; Mozow Yusof Zuidema; Allan W Jones; Leona J Rubin; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

3.  Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells.

Authors:  Kelly J Peyton; Xiao-ming Liu; Yajie Yu; Benjamin Yates; William Durante
Journal:  J Pharmacol Exp Ther       Date:  2012-06-13       Impact factor: 4.030

Review 4.  Adiponectin resistance and vascular dysfunction in the hyperlipidemic state.

Authors:  Rong Li; Wayne Bond Lau; Xin Liang Ma
Journal:  Acta Pharmacol Sin       Date:  2010-08-30       Impact factor: 6.150

5.  AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.

Authors:  Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells.

Authors:  Takao Kimura; Hideaki Tomura; Koichi Sato; Masaaki Ito; Isao Matsuoka; Doon-Soon Im; Atsushi Kuwabara; Chihiro Mogi; Hiroshi Itoh; Hitoshi Kurose; Masami Murakami; Fumikazu Okajima
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

Review 7.  AMP-activated protein kinase: a stress-responsive kinase with implications for cardiovascular disease.

Authors:  Chunying Li; John F Keaney
Journal:  Curr Opin Pharmacol       Date:  2010-01-08       Impact factor: 5.547

Review 8.  AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases.

Authors:  Rai Ajit K Srivastava; Stephen L Pinkosky; Sergey Filippov; Jeffrey C Hanselman; Clay T Cramer; Roger S Newton
Journal:  J Lipid Res       Date:  2012-07-13       Impact factor: 5.922

9.  AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study.

Authors:  J G Boyle; P J Logan; G C Jones; M Small; N Sattar; J M C Connell; S J Cleland; I P Salt
Journal:  Diabetologia       Date:  2011-04-01       Impact factor: 10.122

10.  SHARPIN is an endogenous inhibitor of β1-integrin activation.

Authors:  Juha K Rantala; Jeroen Pouwels; Teijo Pellinen; Stefan Veltel; Petra Laasola; Elina Mattila; Christopher S Potter; Ted Duffy; John P Sundberg; Olli Kallioniemi; Janet A Askari; Martin J Humphries; Maddy Parsons; Marko Salmi; Johanna Ivaska
Journal:  Nat Cell Biol       Date:  2011-09-25       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.